Our Products
Therapy areasFrom core generics to frozen premix and ready-to-use medications, Baxter’s portfolio of products ensures your patients are at the forefront of every decision, across every presentation type, for every bedside.
Ready-to-Use Products
A broad portfolio of IV premixes that are there when you need them, helping to support patient safety while maintaining hospital efficiency.1,2
“We have transitioned from a shelf life of 9 days with our normal compounding operation to now 2 years’ worth of stability with Myxredlin when refrigerated, and 30 days at room temperature. We were excited to introduce it across our entire system because it allows our teams to focus on compounding other non-commercially available products."
Neil Gilchrist, Chief Pharmacy Officer, UMass Memorial Medical Center
Please see accompanying Indications, Important Risk Information, and link to the Prescribing Information for Myxredlin (Insulin Human) in 0.9% Sodium Chloride Injection below.
High Alert Ready-to-Use Products
For high alert medications that carry more risk, ready-to-use formulations help support patient care, safety and workflow efficiency.3
Frozen Premix Products
The safety and reliability of manufacturer-prepared premixes that support patient care while helping to maintain efficiency.1,2
Vials and Other Injectable Medicines
Baxter adds to its portfolio of vials and other injectable medicines continually to ensure patients are able to access the care they require.
Anesthesia Products
Baxter offers a wide range of medications used in all stages of anesthesia and adjuvant therapy, including inhaled anesthetics, injectables, and a postoperative nausea and vomiting [transdermal] patch.
IV Solutions in Mini-Bag Plus Container
Baxter drug reconstitution systems offer options specifically designed for pharmacy and point-of-care needs. Baxter’s Mini-Bag Plus containers are the leading reconstitution drug delivery system in the US.4
Clinical Nutrition
Baxter understands that patients face challenges during their recovery, and the right nutrition regimen can impact outcomes. We provide an extensive portfolio of devices and solutions that help to overcome complexity related to parenteral nutrition.
DoseEdge
DoseEdge Pharmacy Workflow Manager seamlessly integrates with pharmacy information systems to automate the process of routing, preparing, inspecting, tracking, and reporting on IV and oral liquid doses.
MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection
100 units per 100 mL (1 unit/mL)
INDICATIONS AND IMPORTANT RISK INFORMATION
Indication
MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Important Risk Information
Contraindications
• During episodes of hypoglycemia
• Hypersensitivity to insulin human or any of the excipients in MYXREDLIN
Warnings and Precautions
• Hyper- or Hypoglycemia with Changes in Insulin Regimen: Carry out under close medical supervision and increase frequency of blood glucose monitoring.
• Administer MYXREDLIN intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels. Hypokalemia may be life-threatening if not treated.
• Individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal. Dosage adjustments may be needed with changes in nutrition, renal, or hepatic function or during acute illness.
• Adverse reactions observed with insulin human injection include hypoglycemia, allergic reactions, weight gain and edema.
• Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; such as shortness of breath, swelling of your ankles or feet, or sudden weight gain.
Dosage and Administration
• Inspect MYXREDLIN visually before use. It should appear clear and colorless. Do not use MYXREDLIN if particulate matter or coloration is seen.
• Do not add supplementary medication or additives.
• Do not use in series connections.
• Do not shake or freeze. Discard unused portion.
Please see accompanying full Prescribing Information for MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection.